Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18538Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Vartholomatos, G. | en |
| dc.contributor.author | Tsiara, S. | en |
| dc.contributor.author | Christou, L. | en |
| dc.contributor.author | Panteli, A. | en |
| dc.contributor.author | Kaiafas, P. | en |
| dc.contributor.author | Bourantas, K. L. | en |
| dc.date.accessioned | 2015-11-24T18:53:19Z | - |
| dc.date.available | 2015-11-24T18:53:19Z | - |
| dc.identifier.issn | 0001-5792 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18538 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Antibodies, Monoclonal/*therapeutic use | en |
| dc.subject | Antibodies, Monoclonal, Murine-Derived | en |
| dc.subject | Antineoplastic Agents/*therapeutic use | en |
| dc.subject | *Drug Resistance, Multiple | en |
| dc.subject | *Drug Resistance, Neoplasm | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Leukemia, B-Cell/*drug therapy | en |
| dc.subject | Leukemia, Promyelocytic, Acute/*drug therapy | en |
| dc.title | Rituximab (anti-CD20 monoclonal antibody) administration in a young patient with resistant B-prolymphocytic leukemia | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/10529513 | - |
| heal.identifier.secondary | http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000040977 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1999 | - |
| heal.abstract | Following the administration of the human anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab), a 31-year-old woman with B-prolymphocytic leukemia, who had been resistant to CHOP, fludarabine, pentostatin and 2-CdA, achieved complete remission. Rituximab was administered intravenously once a week for 4 weeks. The patient only had mild but tolerable side effects during the first cycle of therapy. She remains in complete remission 8 months following the discontinuation of treatment. | en |
| heal.journalName | Acta Haematol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
